

Memorial Sloan Kettering Cancer Center Workshop on Radiopharmaceutical Therapy (RPT) Normal Tissue Effects in the Clinic (TEC) RPT-TEC-2022

SEPTEMBER 24 - 29, 2022

EISA European Institute for Sciences and Their Applications

Considerations on nephrotoxicity of PRRT

Lisa Bodei, MD, PhD

Attending, Director of Targeted Radionuclide Therapy

Molecular Imaging and Therapy Service

Department of Radiology

Professor of Radiology, Weill Medical College of Cornell University


Monday, September 26, 2022

No Dosimetry, Patient-adjusted Treatments based on Risk factors

¹⁷⁷Lu-DOTATATE

P-NETs

GI-NETs



Paganelli G Neuroendocrinology 2013

Paganelli G EJNMMI 2014


Lower PFS in lower PRRT dosages

Full dose scheme recommended



No difference between dose regimens Risk pts may benefit from PRRT

Predicting Toxicity to PRRT



G3 and G4 toxicity in 807 pts treated at IEO Milan (1997-2013)


Median cumulative activity: •90Y-TOC : 10.1 GBq •90Y-TOC+¹⁷⁷Lu-TATE : 6.4+12.7 GBq

•177Lu-TATE : 22.9 GBq

Grade ^a	All		⁹⁰ Y		⁹⁰ Y+ ¹⁷⁷ Lu		¹⁷⁷ Lu	
	No. of patients	Percent of patients	No. of patients	Percent of patients	No. of patients	Percent of patients	No. of patients	Percent of patients
0	67	8.3	33	9.2	11	7.0	23	7.9
1	410	50.8	147	40.8	75	47.8	188	64.8
2	253	31.4	129	35.8	54	34.4	70	24.1
3	63	7.8	39	10.8	15	9.6	9	3.1
4	14	1.7	12	3.3	2	1.3	0	0
Total	807	100	360	100	157	100	290	100
1/2		82.2		76.7		82.2		89.0
3/4		9.5		14.2		10.8		3.1



Permanent toxicity after PRRT is low and comparable to other treatments *n*=807




Severe nephrotoxicity was virtually absent after 177Lu-peptides
Bone marrow toxicity low and comparable with other anti neoplastic therapies



Memorial Sloan Kettering Cancer Center Bodei L et al. EJNMMI 2015


Nephrotoxicity: Comparative Analysis of Clinical Factor Weight n=807





Memorial Sloan Kettering Cancer Center Bodei L et al. EJNMMI 2015

Dosimetry isn't all...



Unless very high doses are administered, there is a grey zone of unpredictable outcome around the thresholds

Individual susceptibility to adverse *sequelae* of PRRT is likely to have an individual genetic basis.



Bodei L et al. EJNMMI 2015